搜索
60 Degrees Pharmaceuticals Inc
SXTP添加自选
1.710USD
-0.040-2.29%
收盘 07/02, 13:00（美东）报价延迟15分钟
1.75M总市值
亏损市盈率 TTM
关键数据
1.670今开
1.820最高
24.77K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
2.41%换手率
1.750昨收
1.670最低
36.22K成交额
亏损市盈率静
-0.34市净率
0.00%股息率 TTM
-119.00%ROA
14.68052周最高
0.49量比
-8.43M净利润
1.03M总股本
-6.8035每股收益TTM
--Beta
--ROE
1.29052周最低
8.57%振幅
47.12%毛利率
1.75M总市值
1.97回报/风险
7.30%风险率
TradingKey 60 Degrees Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
60 Degrees Pharmaceuticals Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在药品行业排名121/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.70。中期看，股价处于平稳状态。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
60 Degrees Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
60 Degrees Pharmaceuticals Inc亮点
亮点风险
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
业绩高增长
公司营业收入稳步增长，连续3年增长455.70%
业绩增长期
公司处于发展阶段，最新年度总收入1.41M美元
利润高增长
公司净利润处于行业前列，最新年度总收入1.41M美元
估值合理
公司最新PE估值-0.25，处于3年历史合理位
机构加仓
最新机构持股228.38K股，环比增加38.27%
分析师目标
根据
2
位分析师
买入
评级
3.700
目标均价
+111.43%
涨幅空间
60 Degrees Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
60 Degrees Pharmaceuticals Inc简介
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
公司代码SXTP
公司60 Degrees Pharmaceuticals Inc
CEODow (Geoffrey S)
网址https://60degreespharma.com/
相关品种
热门品种
常见问题
60 Degrees Pharmaceuticals Inc(SXTP)的当前股价是多少？
60 Degrees Pharmaceuticals Inc(SXTP)的当前股价是 1.71。
60 Degrees Pharmaceuticals Inc的股票代码是什么？
60 Degrees Pharmaceuticals Inc的股票代码是SXTP。
60 Degrees Pharmaceuticals Inc股票的52周最高点是多少？
60 Degrees Pharmaceuticals Inc股票的52周最高点是14.68。
60 Degrees Pharmaceuticals Inc股票的52周最低点是多少？
60 Degrees Pharmaceuticals Inc股票的52周最低点是1.29。
60 Degrees Pharmaceuticals Inc的市值是多少？
60 Degrees Pharmaceuticals Inc的市值是1.75M。
现在60 Degrees Pharmaceuticals Inc(SXTP)的股票是买入、持有还是卖出？
根据分析师评级，60 Degrees Pharmaceuticals Inc(SXTP)的总体评级为买入，目标价格为3.70。
60 Degrees Pharmaceuticals Inc(SXTP)股票的每股收益（EPS TTM）是多少
60 Degrees Pharmaceuticals Inc(SXTP)股票的每股收益（EPS TTM）是-11.74。